5 not yet recruiting, 1 unknown. 5 Phase 4, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Not yet recruiting 5 |
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Semaglutide weekly injection: new trials by email Literature Review of Semaglutide weekly injection trials Research Report on Semaglutide weekly injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) Semaglutide weekly injection, Placabo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 104 | 2026-10-01 | 2026-10-05 |
| Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus Semaglutide weekly injection - Type 1 Diabetes | Phase 1 / Phase 2 | Unknown | Ministry of Health, Saudi Arabia | 120 | 2024-01-01 | 2023-09-28 |
Obesity, Morbid (5) · Weight Gain (3) · Diabetes Mellitus, Type 1 (1)
General Committee of Teaching Hospitals and Institutes, Egypt (5) · Ministry of Health, Saudi Arabia (1)
Egypt (5)